<DOC>
	<DOCNO>NCT02516423</DOCNO>
	<brief_summary>This randomized phase III trial compare ixazomib citrate , lenalidomide , dexamethasone zoledronic acid zoledronic acid alone see well work give radiation therapy treat patient solitary plasmacytoma bone . Ixazomib citrate may stop growth cancer cell block enzymes need cell growth . Lenalidomide may help immune system kill abnormal blood cell cancer cell . Dexamethasone drug use chemotherapy may cause tumor cell die . Zoledronic acid may prevent bone fracture reduce bone pain , may also improve survival . Standard treatment cancer radiation therapy alone . It yet know whether ixazomib citrate , lenalidomide , dexamethasone zoledronic acid zoledronic acid alone effective , whether add treatment radiation therapy effective radiation therapy alone treat patient solitary plasmacytoma bone .</brief_summary>
	<brief_title>Ixazomib Citrate , Lenalidomide , Dexamethasone , Zoledronic Acid Zoledronic Acid Alone After Radiation Therapy Treating Patients With Solitary Plasmacytoma Bone</brief_title>
	<detailed_description>This phase III randomize clinical trial design assess impact addition ixazomib , lenalidomide , dexamethasone zoledronic acid multiple myeloma progression rate 5 year . A dynamic allocation procedure use allocate equal number patient treatment arm . This procedure balance number patient fall follow category two treatment arm : 1 . % abnormal plasma cell bone marrow : 5-9 % 2. age &lt; 60 ; % abnormal plasma cell bone marrow &lt; 5 % ; monoclonal protein/clonal light chain present blood urine 3. age &lt; 60 ; % abnormal plasma cell bone marrow &lt; 5 % monoclonal protein/clonal light chain present blood urine , ( MRD+ ) minimal residual disease 4. age ≥ 60 ; % abnormal plasma cell bone marrow &lt; 5 % ; monoclonal protein/clonal light chain present blood urine 5. age ≥ 60 ; % abnormal plasma cell bone marrow &lt; 5 % monoclonal protein/clonal light chain present blood urine , ( MRD+ ) minimal residual disease The primary secondary objective describe . Primary objective To assess whether ixazomib , lenalidomide , dexamethasone zoledronic acid promise zoledronic acid alone increase time progression multiple myeloma . Secondary objective 1 . To assess change minimal residual disease [ MRD ] flow cytometry study entry , completion treatment , 1 year post registration . 2 . To assess whether ixazomib , lenalidomide , dexamethasone zoledronic acid promise zoledronic acid alone extend overall survival . 3 . To examine pharmacodynamics effect treatment biochemical marker bone formation ( osteocalcin bone-specific alkaline phosphatase ) , resorption ( serum CTX ) , metabolism ( OPG ) . Follow-up requirement documentation progression multiple myeloma include maximum five year follow registration .</detailed_description>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Ixazomib</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Glycine</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>Preregistration eligibility criterion ( Step 0 ) 1 . Documentation Disease : Histologic Documentation Solitary Bone Plasmacytoma 1 . For patient preregistering completion radiation therapy , documentation bone marrow aspirate biopsy contain &lt; 10 % clonal plasma cell do 28 day prior start radiation therapy 2 . For patient preregistering start radiation therapy , radiation therapy schedule begin 28 day bone marrow aspirate biopsy perform contain &lt; 10 % clonal plasma cell 3 . Participants must disease measurable either serum urine evaluation monoclonal component assay serum free light chain minimal residual detection . Measurable disease define one following : serum M protein &gt; 0.5 G/DL , urine M protein &gt; 200 MG/24H , and/or serum FLC assay : involve FLC level &gt; 10 MG/DL abnormal serum FLC ratio ≥ 50 Plasma cell detectable multicolor flow cytometry , sensitive level 10^4 2 . Age ≥ 18 year 3 . ECOG Performance Status 02 Registration Eligibility Criteria ( Step 1 ) 1 . Documentation Disease : 1 . No lytic lesion skeletal survey whole body PET/CT single lesion associate solitary bone plasmacytoma within 28 day prior registration . 2 . Participants must disease measurable either serum urine evaluation monoclonal component assay serum free light chain minimal residual detection . Measurable disease define one following : serum M protein &gt; 0.5 G/DL , urine M protein &gt; 200 MG/24H , and/or serum FLC assay : involve FLC level &gt; 10 MG/DL abnormal serum FLC ratio ≥ 50 Plasma cell detectable multicolor flow cytometry , sensitive level 10^4 2 . Prior Treatment 1 . No major surgery within 21 day registration stabilization resolution surgical adverse event . 2 . No investigational agent within 21 day prior registration 3 . No ongoing therapy corticosteroid great 10 mg prednisone equivalent per day . Please note : Inhaled topical steroid permit . 4 . No prior proteasome inhibitor IMiD use . 5 . Prior bisphosphonate use permit . 6 . For patient : Radiation dose range 4500 cGy 6000 cGy No treatment disease follow radiation therapy Registration must complete within 90 day completion radiation therapy . 3 . Not pregnant nursing , study involve investigational agent whose genotoxic , mutagenic teratogenic effect develop fetus newborn unknown agent know genotoxic , mutagenic teratogenic effect . 1 . Females childbearing potential ( FCBP ) , define sexually mature female 1 ) undergone hysterectomy bilateral oophorectomy 2 ) naturally postmenopausal least 24 consecutive month , menses time precede 24 consecutive month : must negative serum urine pregnancy test sensitivity least 50 mIU/mL within 10 14 day prior within 24 hour start lenalidomide . must either commit continued abstinence heterosexual intercourse begin TWO acceptable method birth control , one highly effective method one additional effective method AT THE SAME TIME , least 28 day start take lenalidomide . must agree ongoing pregnancy test . 2 . Men must agree use latex condom sexual contact FCBP even vasectomy . 4 . ECOG Performance Status 02 5 . Required Initial Laboratory Values within 14 day registration : 1 . Absolute Neutrophil Count ( ANC ) ≥ 1,500/mm^3 2 . Platelet Count ≥ 75,000/mm^3 3 . Hemoglobin ≥ 10 g/dL 4 . Serum Creatinine &lt; 2.0 mg/dL [ 176.8 µmol/liter ] 5 . Serum calcium ≤ 11.5 mg/dL 6 . Calc . Creatinine Clearance &gt; 50 mL/min 7 . Bilirubin ≤ 1.5 x upper limit normal ( ULN ) 8 . AST ≤ 2.5 x upper limit normal ( ULN ) 6 . Intercurrent Recent Illness 1 . If history prior malignancy , subject complete remission ≥ 5 year time registration ( exception basal cell squamous cell carcinoma skin treat local resection ) . 2 . HIV + patient eligible provided meet eligibility criterion : CD4+ cell ≥ 250/mm^3 There history AIDS defining condition historically low CD4+ cell count . The following antiretroviral agent allow : zidovudine , stavudine , protease inhibitor , combination pill pharmacologic booster . Recommended antiretroviral regimen avoid PK interaction include strand integrase inhibitor nucleoside nonnucleoside reverse transcriptase inhibitor ( example , dolutegravir give tenofovir emtricitabine ) . 3 . Patients HBV infection eligible provide meet eligibility criterion : There evidence hepatic damage relate HBV infection . They consistently suppress HBV viral load undetectable level PCR minimum 12 month . 4 . Patients HCV infection eligible provide meet eligibility criterion : They previously undergo curative therapy evidence active HCV infection . They evidence liver damage owe prior HCV infection . Patients active HCV infection refer HCV treatment standard radiotherapy plasmacytoma . 5 . Patients : Known allergy boron excipients formulation . Known GI disease GI procedure could interfere oral absorption tolerance study drug include difficulty swallowing . Infection require systemic antibiotic therapy serious infection within 14 day registration . Diarrhea ≥ Grade 1 , base NCI CTCAE categorization within 14 day registration Lifethreatening illness unrelated cancer The development erythema nodosum characterize desquamate rash take thalidomide , pomalidomide , similar drug . 7 . Peripheral Neuropathy : ≤ Grade 2 Peripheral Neuropathy 8 . Adequate cardiac function , define : 1 . No cardiac arrhythmia within 182 day registration . 2 . No congestive heart failure ( CHF ) within 182 day registration . 3 . No angina myocardial infarction within 182 day registration . In view potential cardiac risk lenalidomide , patient stable angina exclude . 9 . Concomitant Treatment : Patients systemic treatment strong inhibitor CYP1A2 ( fluvoxamine , enoxacin ) , strong inhibitor CYP3A ( clarithromycin , telithromycin , itraconazole , voriconazole , ketoconazole , nefazodone ) strong CYP3A inducer ( rifampin , rifapentine , rifabutin , carbamazepine , phenytoin , phenobarbital ) within 14 day registration . 10 . QT c &lt; 470 millisecond ( msec ) 12lead ECG ≤ 28 day registration 11 . Dental evaluation within 35 day registration : Complete dental exam ; complete elimination dental periodontal pathology include crown teeth susceptible fracture , extraction nonrestorable periodontally uncorrectable teeth ; creation oral environment patient efficiently maintain high state health ; oral hygiene instruction maintain excellent oral health .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>